HER2 Support Group Forums - View Single Post - New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

News · 09-24-2026, 10:40 AM

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence.

More...

09-24-2026, 10:40 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,135	New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence. More...